Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (9)

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

2023

  1. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

2020

  1. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

2019

  1. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 735-744

2018

  1. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)

    Lung Cancer, Vol. 118, pp. 119-127

2005

  1. Aportación de la tomografía por emisión de positrones a la detección y estadificación del cáncer de mama

    Cirugia Espanola, Vol. 77, Núm. 5, pp. 271-279

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

2001

  1. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial

    Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38